Hemorrhagic Disorders: Clinical Trials

1,639 trials for Hemorrhagic Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

794 completed, 274 terminated, 213 recruiting, 133 unknown. 1639 Phase 1, 607 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11639Completed 794, Terminated 274, Recruiting 213, Unknown 133, Active not recruiting 103, Withdrawn 58, Not yet recruiting 55, Suspended 7, Enrolling by invitation 2
Phase 2607Completed 249, Terminated 111, Recruiting 95, Unknown 68, Active not recruiting 37, Withdrawn 21, Not yet recruiting 20, Suspended 5, Enrolling by invitation 1

Follow Hemorrhagic Disorders: new trials by email Literature Review of Hemorrhagic Disorders trials Research Report on Hemorrhagic Disorders

Trials (filtered) newest first · largest first

All 1,639 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Engineered Dendritic Cell Vaccines for Multiple Myeloma
DC vaccines - Multiple Myeloma or Plasmacytoma
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute102027-06-302026-11-02
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma
Phase 1WithdrawnFred Hutchinson Cancer Center2027-06-012026-09-11
Lentiviral FIX Gene Therapy
YUVA-GT-F901 - Hemophilia B
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute102027-06-012026-11-02
Lentiviral FVIII Gene Therapy
YUVA-GT-F801 - Hemophilia A
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute102027-06-012026-10-30
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)1622027-04-122026-10-16
Topical TOR-582 Treatment of Epistaxis in HHT
Topical sirolimus ointment - Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Phase 1Not yet recruitingColumbia University272027-03-012026-11-06
Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)
Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma
Phase 1Not yet recruitingUniversity of Chicago322027-02-232026-10-22
Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias
RXIM002 - Immune Thrombocytopenia (ITP)
Phase 1Not yet recruitingRiboX Therapeutics Ltd.272027-02-012026-10-28
Regenerative Medicine for Joint Hypermobility and Instability
Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS)
Phase 1 / Phase 2Not yet recruitingManhattan Pain Medicine, PLLC1002027-01-152026-10-06
An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1
CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV)
Phase 1 / Phase 2Not yet recruitingUniversity Hospital Tuebingen362027-01-012026-11-12
Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)
TX002100 - Hereditary Hemorrhagic Telangiectasia (HHT)
Phase 1Not yet recruitingTectonic Operating Company, Inc.202026-12-312026-10-15
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
CAR-T cells - Multiple Myeloma, Plasmacytoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute202026-12-312026-11-02
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
CAR T cells - Multiple Myeloma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute202026-12-312026-10-30
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma
Phase 1 / Phase 2Not yet recruitingUniversitätsklinikum Hamburg-Eppendorf2202026-12-012026-05-20
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM)
Phase 1Not yet recruitingCanadian Myeloma Research Group1082026-12-012026-09-21
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
CAR-T cells, BCMA bispecific - Myeloma Multiple
Phase 1 / Phase 2Not yet recruitingCentre Hospitalier Universitaire de Saint Etienne442026-12-012026-10-09
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Phase 1 / Phase 2Not yet recruitingCullinan Therapeutics Inc.722026-12-012026-07-31
BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma
SL4903 Injection (BCMA/GPRC5D Dual-Target Autologous CAR-T Cell Injection) - Multiple Myeloma; Relapsed/Refractory Multiple Myeloma
Phase 1Not yet recruitingLiping Dou202026-11-302026-11-10
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Mirdametinib, Sirolimus - Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM)
Phase 1 / Phase 2SuspendedNational Cancer Institute (NCI)542026-11-182026-11-13
Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose Administration
NRL-1049, Placebo - Cerebral Cavernous Malformation
Phase 1Not yet recruitingNeurelis, Inc.402026-11-112026-10-30

Showing 20 of 1639. Sign in to see all of them.

Narrower conditions

Multiple Myeloma (1193)  ·  Lymphoma, Non-Hodgkin (244)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (241)  ·  Lymphoma, Follicular (213)  ·  Lymphoma, Mantle-Cell (212)  ·  Waldenstrom Macroglobulinemia (211)  ·  Lymphoma, B-Cell, Marginal Zone (200)  ·  Lymphoma, Large B-Cell, Diffuse (194)  ·  Recurrence (187)  ·  Lymphoma (186)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (181)  ·  Neoplasms, Plasma Cell (168)  ·  Hodgkin Disease (164)  ·  Leukemia, Myeloid, Acute (155)  ·  Burkitt Lymphoma (150)

Broader conditions

Hemic and Lymphatic Diseases (1639)  ·  Hematologic Diseases (1599)  ·  Immune System Diseases (1422)  ·  Cardiovascular Diseases (1388)  ·  Vascular Diseases (1385)  ·  Hemostatic Disorders (1359)  ·  Neoplasms by Histologic Type (1358)  ·  Immunoproliferative Disorders (1347)  ·  Lymphoproliferative Disorders (1335)  ·  Blood Protein Disorders (1334)  ·  Paraproteinemias (1328)  ·  Neoplasms (1306)  ·  Neoplasms, Plasma Cell (1177)  ·  Pathological Conditions, Signs and Symptoms (533)

Interventions

Dexamethasone (265)  ·  Lenalidomide (140)  ·  Bortezomib (133)  ·  Cyclophosphamide (116)  ·  Calcium Dobesilate (97)  ·  pomalidomide (84)  ·  carfilzomib (72)  ·  Melphalan (70)  ·  daratumumab (61)  ·  fludarabine (59)  ·  fludarabine phosphate (52)  ·  Rituximab (49)  ·  Peripheral Blood Stem Cell Transplantation (39)  ·  Filgrastim (38)  ·  dexamethasone acetate (35)

Sponsors

National Cancer Institute (NCI) (75)  ·  Mayo Clinic (39)  ·  Celgene (34)  ·  M.D. Anderson Cancer Center (27)  ·  Novo Nordisk A/S (27)  ·  Memorial Sloan Kettering Cancer Center (26)  ·  GlaxoSmithKline (25)  ·  Fred Hutchinson Cancer Center (24)  ·  AbbVie (22)  ·  Amgen (20)  ·  City of Hope Medical Center (18)  ·  Janssen Research & Development, LLC (18)  ·  Novartis Pharmaceuticals (18)  ·  Pfizer (18)  ·  Bayer (15)

Countries

United States (1086)  ·  China (206)  ·  Spain (154)  ·  France (132)  ·  Australia (123)  ·  United Kingdom (120)  ·  Germany (118)  ·  Canada (107)  ·  Italy (101)  ·  Japan (74)  ·  South Korea (62)  ·  Israel (51)  ·  Netherlands (48)  ·  Belgium (39)  ·  Poland (37)

Results publications

PMID 34398557, PMID 36100310, PMID 37022569, PMID 25495795, PMID 28803351, PMID 32499241, PMID 34515338, PMID 35075289, PMID 37192741, PMID 17880439, PMID 19238148, PMID 22149959, PMID 26370838, PMID 26943915, PMID 27412889, PMID 29224506, PMID 31215818, PMID 31527168, PMID 33980831, PMID 35857660, PMID 36375120, PMID 36796484, PMID 37270762, PMID 37658205, PMID 39642315, PMID 40000533, PMID 40386832, PMID 40826257, PMID 41100731, PMID 41118600, PMID 42287565, PMID 42698050, PMID 10552943, PMID 10564685, PMID 10613347, PMID 10764422, PMID 12171484, PMID 12473574, PMID 12752100, PMID 1374895, PMID 14767498, PMID 15230949, PMID 15241836, PMID 1538192, PMID 15466934, PMID 15570084, PMID 15577929, PMID 15870545, PMID 15902208, PMID 15958804

NIH funding

2023 (43), P30CA015083 (20), 2019 (18), 2018 (17), 2015 (14), 2016 (12), 2014 (10), 2017 (10), 2025 (9), P30CA006973 (9), U01CA076576 (9), P30CA016058 (8), U01CA069912 (8), 2009 (7), P30CA015704 (7)